{ }
001122334455554433221100
001122334455554433221100

Roche emphasizes fixed-duration dosing in bispecifics competition for B-cell lymphomas

Roche is emphasizing the advantages of fixed-duration dosing for its bispecific therapies, Lunsumio and Columvi, in the competitive landscape against AbbVie/Genmab’s Epkinly for B-cell lymphomas. The outcome of ongoing Phase III studies may significantly influence market positioning.Meanwhile, Ken Mulvany has returned to lead BenevolentAI through a restructuring aimed at refocusing on its core strengths and plans to delist from Euronext Amsterdam. In another setback, Cervomed's shares plummeted nearly 80% after its lead product, neflamapimodin, failed in a Phase IIb trial for Lewy body dementia, raising questions among investors about the trial's shortcomings.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.